{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Natural Product[C66892]|Plant-based Natural Product[C106104]|Plant or Plant Part Extract" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2011)
Source URL:
First approved in 2011
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01628705: Phase 4 Interventional Completed Nutritional and Metabolic Disease
(2007)
Source URL:
First approved in 2009
Source:
Sumaxin Cleansing Pads by Medimetriks Pharmaceuticals, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2009)
Source URL:
First approved in 2009
Source:
21 CFR 333D
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2009
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04656730: Phase 4 Interventional Completed Irritable Bowel Syndrome
(2020)
Source URL:
First approved in 2009
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 341
(2012)
Source URL:
First approved in 2007
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M021
(2024)
Source URL:
First approved in 2005
Source:
Numark Multivitamins by NUMARK BRANDS, INC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02982603: Phase 4 Interventional Completed Mild Cognitive Impairment
(2015)
Source URL:
First approved in 1999
Source:
M012
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 358B
(2010)
Source URL:
First approved in 1976
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE